Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Oral selinexor induced durable responses on relapsed or refractory DLBCL patients

Key clinical point: Oral selinexor induced durable responses with manageable adverse events in

patients with relapsed or refractory DLBCL.

Major finding: The overall response rate was 28%; 12% achieved a complete response and 17% a partial response.

Study details: A total of 267 DLBCL patients were enrolled in the single-arm, multinational, multicenter, open-label, phase 2 SADAL trial.

Disclosures: The study was sponsored by Karyopharm Therapeutics Inc., author funding. In sentence form. The authors reported various relationships with multiple pharmaceutical and biotechnology companies.

Citation:

Kalakonda N et al. The Lancet: Haematology. 2020; 7:e511-22.